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Malignant cells show increased glucose uptake both in
vitro and in vivo [1,2]. This uptake is mediated by glu-
cose transporters (GLUT), while expression and activ-
ity are regulated by oncogenes and growth factors
[3–6]. GLUT1, the human erythrocyte glucose trans-
porter, is a member of the facilitative glucose trans-
porter family, which is composed of six members [7].
The physiologic expression and immunohistochemical
detection of GLUT1 are demonstrated in red blood cell
membranes, brain capillary endothelium (the blood–
brain barrier) [8], the perineurium of the peripheral
nerve (all interface with cells or tissues with glucose-
derived metabolism) [9], placenta [10], and basal cells
of benign squamous epithelium [11]. A number of
immunohistochemical studies have demonstrated
aberrant expression of GLUT1 in epithelial neoplasms,
as well as a correlation between GLUT1 expression and
neoplastic progression [11–17]. GLUT1 have also been
detectable in over 50% of head and neck cancers [18],
renal cell carcinoma [19], malignant endometrial 
epithelia [20], non-small cell lung carcinoma [21],
esophageal Barrett-associated adenocarcinoma [22],
papillary thyroid carcinoma [14], cholangiocarcinomas
[17], and breast carcinomas [23,24].
The incidence of breast cancer has been increasing
in Taiwan. In patients with breast cancer, mastectomy
combined with chemotherapy and/or radiotherapy
leads to the achievement of high response rates and
prolongs survival. Modern treatment approaches for
breast cancer require individual determination of the
therapeutic strategy, in accordance with tumor stage
and prognosis. Several factors are reportedly predictive
of tumor response to chemotherapy and subsequent
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transporter-1 gene (GLUT1) has been found in many human tumor tissues. The aim of this study
was to investigate the correlation between GLUT1 expression in breast carcinomas of Taiwanese
patients and clinical prognostic parameters. Twenty-eight (71.8%) of the 39 breast carcinomas
analyzed showed positive GLUT1 expression with different intensities: 1, 19 cases (48.7%); 2,
6 cases (15.4%), 3, 3 cases (7.7%). No significant correlation was seen between GLUT1 expres-
sion and clinical prognostic parameters such as tumor size (p0.085), age (p0.4528), axillary
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patient survival. These factors include the prolifera-
tion rate, estrogen and progesterone levels, gene p53,
and the proto-oncogene c-erb B2 [25].
According to previous studies, aberrant expression
of GLUT1 in epithelial neoplasms as well as a corre-
lation between GLUT1 expression and neoplastic
progression have been found. The aim of our study
was to investigate the relationship between the GLUT1
gene and the progression of breast cancer.
MATERIALS AND METHODS
We examined the expression and distribution of 
the GLUT1 gene and its relationship to clinicopatho-
logic parameters in patients with breast cancer.
GLUT1-positive and GLUT1-negative carcinomas
were analyzed for their clinicopathologic character-
istics including tumor size, age, lymph node metasta-
sis, estrogen receptor (ER), progesterone receptor (PR),
and nuclear grade.
Tissue
Thirty-nine formalin-fixed, paraffin-embedded breast
cancer tissues and 39 breast carcinoma tissue sections
containing normal tissue were examined by GLUT1
immunohistochemical staining (Figure). All patients
were between the ages of 29 and 82 years and under-
went partial or total mastectomy at the China Medical
University Hospital in Taichung, Taiwan between
December 1999 and December 2001.
Immunohistochemistry
Three to four sections (m) of tissues were cut and
mounted onto poly-L-lysine-coated slides (DAKO,
Copenhagen, Denmark). The tissue sections were
dewaxed in two changes of xylene and placed in
absolute ethanol for 1 minute. The sections were
immersed in flowing water for 2 minutes, and then
microwaved in the retrieval solution (DAKO) for 12
minutes. After microwaving, the sections were
immersed in distilled water with 3% hydrogen perox-
ide for 10 minutes to block endogenous peroxidase
activity in the tissue. After three 2-minute washes in
phosphate-buffered saline (PBS), the sections were cov-
ered with 100L of serum-blocking solution (ZYMED
NBATM KIT; Zymed Laboratories Inc, South San
Francisco, CA, USA) for 10 minutes to reduce back-
ground staining. Any excess serum blocking solution
was drained, and the sections were incubated with a
1:400 dilution primary antibody GLUT1 (DAKO) for 60
minutes at 25C. Following three 2-minute washes in
PBS, the sections were incubated with 100L of sec-
ondary antibody (ZYMED NBATM KIT) for 10 minutes.
After three 2-minute washes in PBS, the sections were
incubated with 100 μL of tertiary antibody–enzyme
conjugate (ZYMED NBATM KIT) for 10 minutes. After
three 2-minute washes in PBS, the sections were
immersed in a DAB solution (ZYMED kit) for 5 min-
utes. Finally, after three 2-minute washes in distilled
water, the sections were counterstained with Mayer’s
hematoxylin (Sigma Chemical Co, St Louis, MO, USA),
dehydrated through increasing concentrations of
ethanol, and then mounted. Placenta tissue was used
as the antibody concentration test and positive control
for each experiment as illustrated in part A of the
Figure. Membranous staining in tumor cells was
indicative of GLUT1 expression.
Positive/negative
Tumors were determined positive if any tumor cells
stained brown, or negative if tumor cells did not stain
brown. All determinations were made by a pathologist.
Intensity of staining
The intensity of tumor staining was graded on a scale
of 0–3, wherein 0no positive staining of tumor
cells; 1weak positive staining; 2moderately strong
positive staining; and 3strong positive staining of
tumor cells.
Statistical analysis
The expression of GLUT1 was compared with clinico-
pathologic features such as tumor size, lymph node
metastasis, ER, PR, and nuclear grade. All statistical
tests were performed by either the Fisher’s exact or
2 tests; p values 0.05 were considered statistically
significant.
Follow-up
All patients were followed up for 2 years to assess
recurrence and survival.
RESULTS
In addition to breast carcinoma, 39 paraffin-embedded
breast carcinoma tissue sections containing normal
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tissues were examined by GLUT1 immunohistochem-
ical staining (Figure). Twenty-eight (71.8%) of the 39
breast carcinomas showed positive GLUT1 expression
with varying degrees of intensity: 1, 19 cases (48.7%);
2, 6 cases (15.4%), 3, 3 cases (7.7%) (Table 1).
The correlations between GLUT1 expression and
several clinicopathologic prognostic parameters are
shown in Table 2. There were no significant differ-
ences in GLUT1 expression and tumor size (p
0.085), age (p0.4528), axillary lymph node metasta-
sis (p0.9562), nuclear grade (p0.6895), ER posi-
tivity (p1.0000), and PR positivity (p0.9689). At
the 2-year follow-up, breast carcinoma recurred in 6
(15.4%) cases and the overall survival rate was 89.7%.
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Figure. Immunohistochemical staining of GLUT1: (A) GLUT-1 pos-
itive control in placenta; (B) strong positive; (C) moderately positive;
(D) weak positive; (E) negative (B–E are invasive ductal carcinoma of
breast tissues).
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There was no correlation between GLUT1 expression
and either recurrence (p1.0000) or survival rate
(p0.4528).
DISCUSSION
Increased rates of glycolysis in cancer cells provide
an adequate supply of energy, enabling malignant
cells to survive and proliferate. In a study by Brown
et al, the expression of GLUT1 in breast cancer tissues
was highly heterogeneous in both the extent and
intensity of staining [26]. In our study, the cell mem-
brane and the cytoplasmic granules were GLUT1-
positive in all breast cancer cells. The percentage of
GLUT1-positive tissues (71.8%) was higher than that
reported for the same antibody by Kang et al (47%)
[27]. These differences may have been related to dif-
ferences in patient populations or tumor types.
Some normal and hyperplastic mammary epithe-
lial cells in tumor-free areas were GLUT1-positive;
however, the intensity of staining in these cells was
lower than in cancer cells. GLUT1-positive normal
mammary cells exhibited a diffuse cytoplasmic stain-
ing, unlike the cancer cells, and their cell membranes
were GLUT1 negative. Kang et al found that GLUT1
expression correlates with negative ER, negative PR,
high nuclear grade, and poor disease-free survival [27].
Table 1. Glucose transporter GLUT1 expression in
breast carcinoma tissues
Expression of Number of
GLUT1 patients
Positive 28
1 19
2 6
3 3
Negative 11
Table 2. Expression of GLUT1 and clinicopathologic prognostic parameters
Clinicopathologic GLUT1 GLUT1
parameters
Cases
positive, n negative, n
p
All 39 — — —
Tumor size (cm) 39 — — —
2 7 (18%) 3 4 0.0825
2 32 (82%) 25 7 —
Age (yr)
	60 13 (33%) 8 5 0.4528
60 26 (67%) 20 6 —
Axillary lymph 39 — — —
node metastasis
Positive 21 (54%) 15 6 0.9562
Negative 18 (46%) 13 5 —
Nuclear grade 38 — — —
2 26 (67%) 18 8 0.6895
3 10 (26%) 8 2 —
ER 38 — — —
Positive 22 (56%) 16 6 1.0000
Negative 16 (41%) 12 4 —
PR 37 — — —
Positive 17 (44%) 12 5 0.9689
Negative 20 (51%) 14 6 —
Survival 32 (82%) 23 9 0.5705
Death 4 (10%) 2 2 —
Recurrence 8 (21%) 6 2 1.0000
No recurrence 31 (79%) 22 9 —
Although the same antibody was used, there were no
statistically significant findings in our study. A pos-
sible explanation may be that the patient population
differed in each study. With the exception of three
patients, the breast tumor cell types in our study
were all invasive ductal carcinoma. The expression
and activity of facilitative glucose transporters is reg-
ulated by various types of oncogenes and growth fac-
tors. Perhaps different environmental signals induce
GLUT1 expression.
Artificial menopause (surgical oophorectomy or
radiation ovarian ablation) before the age of 35 years,
increasing parity, young age (30 years) at first preg-
nancy and breast-feeding are protective factors against
developing breast cancer. Conversely, breast cancer is
more common in women with an early menarche or a
late menopause. In addition, women (60 years) may
be at increased risk of developing breast cancer. In our
study, no statistically significant correlation was found
between GLUT1 expression and age (p0.4528).
However, this may have been due to the small sample
size. In our study, 28 (71.8%) of the 39 breast carcino-
mas showed positive GLUT1 expression. However,
no significant correlation was seen between GLUT1
expression and either clinical prognostic parameters,
recurrence rate, or survival rate.
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